| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.12.23 | Regeneron Pharmaceuticals, Inc.: Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes | 208 | GlobeNewswire (Europe) | Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate (ORR), with 31% achieving a complete response (CR) Results from a Phase 1 expansion cohort... ► Artikel lesen | |
| 10.12.23 | Vincerx Pharma, Inc.: Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023 | 160 | GlobeNewswire (Europe) | Poster on VIP943, a novel CD123-targeted antibody-drug conjugate (ADC) from our VersAptx platform, showcases selectivity, activity, and safety of VIP943 Poster on VIP924, a first-in-class CXCR5-targeted... ► Artikel lesen | |
| 10.12.23 | Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting | 233 | GlobeNewswire (Europe) | Initial antitumor activity observed in early MP0533 dose-escalation cohorts, with a previously undisclosed complete response (CR) observed in dose range four, in addition to the previously reported... ► Artikel lesen | |
| 10.12.23 | Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023 | 144 | GlobeNewswire (Europe) | REDWOOD CITY, Calif., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy... ► Artikel lesen | |
| 10.12.23 | Nkarta, Inc.: Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition | 308 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today... ► Artikel lesen | |
| 10.12.23 | Autolus Therapeutics plc: Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 | 180 | GlobeNewswire (Europe) | Pooled analysis of the FELIX Phase Ib/II study demonstrated prolonged event free survival and low overall immunotoxicity across all cohorts in r/r B-ALL, and particularly in patients with low leukemic... ► Artikel lesen | |
| 10.12.23 | Agios Pharmaceuticals, Inc.: Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition | 150 | GlobeNewswire (Europe) | - Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo - - Improvements Observed in Annualized Rates of Sickle Cell Pain Crises, Markers... ► Artikel lesen | |
| 10.12.23 | Aptose Biosciences, Inc.: Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting | 151 | GlobeNewswire (Europe) | Reporting Complete Response Data from the Ongoing APTIVATE International Phase 1/2 Study of Tuspetinib (TUS) in Relapsed/Refractory AML PatientsTUS Single Agent and TUS/VEN Combination Demonstrate... ► Artikel lesen | |
| 10.12.23 | Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia | 543 | GlobeNewswire (Europe) | Part 5 data reinforces favorable safety and tolerability profile and long-term efficacy results for SerpinPC:
Median all-bleed ABR of 1.0, a 96% reduction from prospective baseline No thromboembolic... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 423 |
| BAYER | 272 |
| BYD | 240 |
| NVIDIA | 228 |
| NEL | 226 |
| PLUG POWER | 200 |
| TESLA | 191 |
| TUI | 189 |
| SUPER MICRO COMPUTER | 186 |
| DEUTSCHE BANK | 184 |
| APPLE | 182 |
| RHEINMETALL | 159 |
| RWE | 148 |
| AMAZON | 145 |
| DEUTSCHE LUFTHANSA | 144 |
| MERCEDES-BENZ | 142 |
| BERKSHIRE HATHAWAY | 127 |
| COMMERZBANK | 117 |
| BIONTECH | 116 |
| PAYPAL | 115 |
| ALLIANZ | 113 |
| AIXTRON SE | 110 |
| BASF | 110 |
| RENK GROUP | 110 |
| VOLKSWAGEN | 107 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
